Hey ox, with the sp where it is at, I to am wondering if I have missed some red flag.
That said I am prepared to go the distance with Admedus and review in the New Year.
Am prepared to wait and judge Admedus mangerment by its future results, not sure how any other mangerment could have done anything different to have the sp any higher. Until this time all WP (with team) decisions seen to be solid and have substance.
IF all is 'well' should bear fruit by end of this year, proviso being a announcement clarificating the direction of the immunotherapies division.
What really interests me is the clafication on the immunotherapies division, I do not think, imo, that dropping the hsv-2 R&D but continuing with the hpv R&D will appease the market. More than happy to eat 'crow' and say I got it wrong!
The ultimate 'rabbit' out of the hat would be a 'paying' pharma coming to the table.
I am allowing the drifting sp to be accounted, to some extent, by eofy selling off.
Would hope and expect it to recover a little by end of July, imo.
Hey ox, with the sp where it is at, I to am wondering if I have...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.035(0.19%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $17.65 | $75.19K | 4.184K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 414 | $17.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |